Tracer library / [225Ac]Ac-J591
[225Ac]Ac-J591
Also written as [Ac-225]Ac-J591; Ac-225-J591
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 0
What it is
- Compound class
- Anti-PSMA monoclonal antibody radioconjugate
- Target / mechanism
- Targets prostate-specific membrane antigen (PSMA) via monoclonal antibody J591 PMID 37922438
- Clinical application
- Radioligand (radioimmuno-) therapy for metastatic castration-resistant prostate cancer PMID 37922438
- Theranostic pair
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.2024 · J Clin Oncol · Clinical study · Phase I
Need this precursor?We can point you to suppliers for [225Ac]Ac-J591, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 37922438: 'To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals.'. | Stage 30 (2026-09-18): Stage was 'first-in-human phase I dose-escalation trial'; normalised to 'Clinical research', original wording kept here.